Publications (original articles or review articles) published in 2024 from OUS - Department of Cancer Genetics
28 publications found
Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia
Cell Rep Med, 5 (5), 101521
DOI 10.1016/j.xcrm.2024.101521, PubMed 38653245
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720
Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
Int J Cancer, 155 (2), 282-297
DOI 10.1002/ijc.34915, PubMed 38489486
A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cells
Sci Adv, 10 (21), eadj1564
DOI 10.1126/sciadv.adj1564, PubMed 38781347
Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer
Clin Exp Med, 24 (1), 10
DOI 10.1007/s10238-023-01273-0, PubMed 38240952
High-throughput molecular assays for inclusion in personalised oncology trials - State-of-the-art and beyond
J Intern Med, 295 (6), 785-803
DOI 10.1111/joim.13785, PubMed 38698538
Protocol to identify defined reprogramming factor expression using a factor-indexing single-nuclei multiome sequencing approach
STAR Protoc, 5 (3), 103148 (in press)
DOI 10.1016/j.xpro.2024.103148, PubMed 38909361
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
ESMO Open, 9 (6), 103464
DOI 10.1016/j.esmoop.2024.103464, PubMed 38833971
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
Mol Oncol (in press)
DOI 10.1002/1878-0261.13656, PubMed 38671580
Lung cancer reirradiation: Exploring modifications to utilization, treatment modalities and factors associated with outcomes
J Med Imaging Radiat Sci, 55 (2), 221-231
DOI 10.1016/j.jmir.2024.02.004, PubMed 38429174
[Raising the quality of cancer treatment]
Tidsskr Nor Laegeforen, 144 (1)
DOI 10.4045/tidsskr.23.0740, PubMed 38258713
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379
RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies
Brief Bioinform, 25 (4)
DOI 10.1093/bib/bbae328, PubMed 38980370
A federated learning system for precision oncology in Europe: DigiONE
Nat Med, 30 (2), 334-337
DOI 10.1038/s41591-023-02715-8, PubMed 38195748
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Acta Oncol, 63, 213-219
DOI 10.2340/1651-226X.2024.24179, PubMed 38647024
ScType enables fast and accurate cell type identification from spatial transcriptomics data
Bioinformatics, 40 (7)
DOI 10.1093/bioinformatics/btae426, PubMed 38936341
Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1)
ESMO Open, 9 (6), 103475
DOI 10.1016/j.esmoop.2024.103475, PubMed 38838499
The Tumor Immune Microenvironment in Breast Cancer Progression
Acta Oncol, 63, 359-367
DOI 10.2340/1651-226X.2024.33008, PubMed 38779867
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023
Mol Oncol, 18 (2), 245-279
DOI 10.1002/1878-0261.13575, PubMed 38135904
Copy number alterations: a catastrophic orchestration of the breast cancer genome
Trends Mol Med (in press)
DOI 10.1016/j.molmed.2024.04.017, PubMed 38772764
Preoperative profiles of plasma amino acids and derivatives distinguish periampullary cancer and benign disease
BMC Cancer, 24 (1), 555
DOI 10.1186/s12885-024-12320-8, PubMed 38702616
Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
J Clin Invest, 134 (8)
DOI 10.1172/JCI168536, PubMed 38618957
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Acta Oncol, 63, 385-391
DOI 10.2340/1651-226X.2024.34791, PubMed 38779910
Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma
Heliyon, 10 (13), e33525
DOI 10.1016/j.heliyon.2024.e33525, PubMed 39050459
Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses
Blood (in press)
DOI 10.1182/blood.2023022884, PubMed 38941598
Tutorial on survival modeling with applications to omics data
Bioinformatics, 40 (3)
DOI 10.1093/bioinformatics/btae132, PubMed 38445722